Saving more Filipinos from another mosquito-borne disease | Inquirer Business

Saving more Filipinos from another mosquito-borne disease

/ 10:27 PM December 06, 2013

Next to dengue, Japanese encephalitis or JE is perhaps one of the diseases that Filipino families should watch out for. Similar to dengue, the disease is spread by mosquitoes—Culex species—infected with the JE virus.

JE can be difficult to diagnose because in most individuals it causes nonspecific initial symptoms. While it begins like a flu (head and body aches, fever and tiredness), JE progresses to neck stiffness and convulsions, and ends by killing up to 30 percent of its victims and  leaving thousands more with neurological impairment.

Because the disease is difficult to diagnose and awareness of it is low, the global incidence of JE is unknown. Nevertheless, the World Health Organization estimates that JE claims 10,000 to 15,000 lives a year. Moreover, the international health organization PATH estimates that three billion people live in areas at risk for JE and up to 60,000 cases are reported annually.

Article continues after this advertisement

Vaccine introduced

FEATURED STORIES

Dr. Ruby Dizon, medical director of Sanofi Pasteur, said: “Over half of people who survive a case of Japanese encephalitis experience longer-term psychosocial, behavioral or motor deficits. This can lead to complications such as learning difficulties, behavioral problems and more subtle neurological signs.” Sanofi Pasteur recently introduced a vaccine that confers rapid, high-level protection against JE with just one primary dose.

Considering that there is no treatment for JE, prevention by getting immunized with a JE vaccine may be regarded as the only viable solution. This is the first time a single-dose vaccine against JE is available in the Philippines.

Article continues after this advertisement

“With a single primary vaccination, the vaccine could protect one from JE,” explained Dizon. He added that tourists and business travelers, medical and military personnel as well as those living or staying in areas where cases have been detected would benefit from the immunization.

Article continues after this advertisement

Dizon said one should realize the lifelong toll that JE takes on its survivors. Up to half of them suffer permanent neurological damage, such as paralysis, recurrent seizures, or the inability to speak.

Article continues after this advertisement

Since late 1800s

JE was first recognized in Japan in the late 1800s. Since then, the disease has increasingly been recognized throughout most countries of East and Southeast Asia, where it is the leading cause of childhood viral encephalitis.

Article continues after this advertisement

Interestingly, while the incidence of JE varies by country and is usually seasonal, the disease occurs all year round in Malaysia, Indonesia and the Philippines, where rain falls throughout the year.

The JE virus is hosted by wading birds like herons and egrets, which flock to rice paddy fields and by the pigs raised in farms. Thus, transmission principally occurs in areas within or near ricefields, flood irrigation, swamps and marshes.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

The JE vaccine was introduced during the 14th Philippine national immunization conference on Nov. 7 at Summit Ridge, Tagaytay City. The event was attended by vaccine advocates from both private and public sectors aiming to sustain the reduction of vaccine preventable diseases.

TAGS: dengue, health and wellness, vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.